HanAll Biopharma Releases Q2 2023 Financial Results and Business Update

HanAll Biopharma Co., Ltd. (KRX: 009420. KS), a leading global biopharmaceutical company dedicated to pioneering innovative treatments for patients, has released its financial results for the second quarter, showcasing remarkable achievements.

During Q2 2023, HanAll recorded a remarkable sales figure of KRW 41.4 billion, marking an impressive 58 percent increase compared to the same period last year. This substantial growth was mainly attributed to the sustained robust performance of its major products and significant milestone revenues derived from the progress made in clinical programs involving batoclimab.

Furthermore, HanAll Biopharma reached multiple critical milestones in clinical development during the quarter. Notably, the company announced the top-line result of the VELOS-3 trial, and they successfully submitted a Biologics License Application (BLA) for batoclimab in China, signaling significant progress in bringing this potential treatment to patients.

The company's commitment to advancing disease-modifying medicines for neurodegenerative diseases remains unwavering. Throughout the second quarter, HanAll continued to engage in strategic collaborations aimed at developing groundbreaking therapies with the potential to transform the treatment landscape for these conditions.

Overall, HanAll Biopharma's financial performance and remarkable progress in clinical programs reinforce its position as a trailblazing force in the biopharmaceutical industry, solidifying its dedication to enhancing patient care and delivering innovative solutions to global healthcare challenges.

Next article